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IL4-10 SYNERKINE TO INDUCE DIRECT AND INDIRECT STRUCTURAL
CARTILAGE REPAIR IN OSTEOARTHRITIS
M.F. Pustjens, C. Steen-Louws, C.E. Hack, J.A. Van Roon,
S.C. Mastbergen, F.P. Lafeber. Univ. Med. Ctr. Utrecht, Utrecht, Netherlands
Purpose: Progressive articular cartilage degradation is central to
osteoarthritis (OA), and is driven by mechanisms of cartilage matrix
catabolic effects and anti-anabolic effects of chondrocytes. However, OA
is a disease mediated by and affecting the entire synovial joint organ.
Chronic, low-grade synovial inﬂammation contributes to symptoms
and disease progression. We recently developed IL4-10 synerkine, a
fusion protein composed of IL-4 and IL-10. It is demonstrated that these
cytokines inhibit production of pro-inﬂammatory cytokines such as IL-
1b, IL-6 and TNFa (Fiorentino, 1991; Hart, 1995; Lee, 2002), all impor-
tant in the degeneration of cartilage and inﬂammation of synovium in
osteoarthritis (Liu-Bryan and Terkeltaub, 2014). In human and animal in
vivo and in vitro experimental models the individual cytokines and IL-4
and IL-10 combined are shown to be effective. However, clinically
effects are modest, most likely due to limited bio-availability and
insufﬁcient immunosuppression. IL4-10 synerkine might overcome
these limitations and may successfully achieve structural repair in
diseases like OA because of synergistic effects of the cytokines. The
purpose of this study is to evuate the cartilage protective and anti-
inﬂammatroy effects of IL4-10 synerkine ex vivo.
Methods: Cartilage from the condyles of seven end-stage knee OA
patients selected for total knee replacement, was cultured for 4 days in
presence or absence of IL-4 (10ng/ml), IL-10 (10ng/ml), a combination of
IL-4 (10ng/ml) and IL-10 (10ng/ml), or IL4-10 synerkine (20ng/ml).
Changes in proteoglycan (PG) synthesis and PG release were studied.
Synovial tissue from six OA donors selected for total knee replacement
was cultured for 3 days under similar circumstances. Cytokine levels in
culture medium supernatants of both cartilage and synovium cultures
were measured by ELISA for IL-6, IL-8 and TNFa.
Results: Culturing OA cartilage in presence of IL4-10 synerkine
increased proteoglycan (PG) synthesis with 47.6% (p¼0.018), þ26.6% for
IL-4 alone,þ31.2% for IL-10 alone, orþ6.9% for IL-4 and IL-10 combined.
Only a small reduction of -8.7% (p¼0.018) in PG release was found for
the IL4-10 synerkine (-4.9% for IL-4 alone, -8.6% for IL-10 alone, or -6.7%
for IL-4 and IL-10 combined). The overall improved proteoglycan
turnover was in cocurrence with a signiﬁcant inhibition of Il-6, IL-8 and
TNF-a cytokine production by the cartilage in presence of the IL4-10
synerkine (IL-6 -81.9%, IL-8 -65.9% and -2.0% TNF-a, resp.). Moreover,
IL4-10 synerkine also reduced the production of IL-6, IL-8 and TNFa in
osteoarthritic synovium (-83.5%, -85.6% and -25.9% resp., all p<0.01).Conclusions: These data show that IL4-10 synerkine might induce both
structural repair and reduce inﬂammation in OA. Ex vivo, IL4-10 syn-
erkine has a direct effect on OA cartilage by affecting its proteoglycan
turnover and cytokine production. Inhibiting the synovial cytokine pro-
duction, adds indirectly to this structural repair of the cartilage. Together
with the pain inhibiting effects found in animal models of OA, these data
suggest disease modifying characteristics of the IL4-10 synerkine.
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KARTOGENIN LOADED PHOTO-CROSSLINKABLE SCAFFOLD FOR
CARTILAGE REGENERATION
D. Shi, x. Xu, Q. Jiang. Sports Med. and Adult Reconstruction, Nanjing,
China
Purpose: Hyaline cartilage injury, a common disease is seriously
affected the life quality of the patient and difﬁcult to be cured. Recently,
various kinds of methods have been conducted to solve this problem.
Scaffold-based cartilage tissue engineering is a promising one. Although
positive results were reported in many in vivo cartilage repair studies
with cartilage tissue engineering, adverse effects were also detected
because of using growth factors or exogenous cells. In this study, we
used a small molecule Kartogenin (KGN) loaded photo-crosslinkable
scaffold to restore cartilage defects through a cell homing way.
Methods: Small molecule KGN was synthesized and its chondrogenic
ability was tested on human synovium derived mesenchymal stem cells
(SMSCs). PLGA nanoparticles loaded with KGN were prepared by a
single oil-in-water (O/W) emulsion/solvent evaporation method. Hya-
luronic acid (HA) was modiﬁed with double bond by reacting with the
methacrylic anhydride (MA). The HA hydrogel encapsulating KGN loa-
ded PLGA nanoparticles (HA/KGN-NPs) can be formed by UV irradiation
for 30 s, and in vitro drug released study was studied. Full-thickness
cartilage defects were created in New Zealand White animals and the
HA/KGN-NPs were used to repair them in vivo. The animals were sac-
riﬁced at 4 and 12 weeks after operation. Histology and immunohis-
tochemistry were used to evaluate the repair quality.
Results: KGN had the ability to induce human SMSCs into chondrocytes
in vitro. The sustained release of KGN from PLGA nanoparticles and
hyaluronic acid hydrogel encapsulating PLGA nanoparticles at 37 oC
was found. After HA/KGN-NPs hydrogel was formed in cartilage defects
for 4 and 12 weeks, toluidine blue staining, safranin O staining and
immunohistology staining for type I and type II collagen all showed
signiﬁcantly better restoration.
Conclusions: This ultraviolet-reactive, rapidly cross-linkable scaffold
with KGN releasing is a great therapoutic candidate for cartilage defects.
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POLYELECTROLYTE MICROENCAPSULES LOADED WITH C-TYPE
NATRIURETIC PEPTIDE PROTECT CARTILAGE FROM IL-1B INDUCED
DAMAGE
N. Peake y, A. Pavlov y, A. D'Souza y, I. Alfasahin z, B. Pingaan-Murphy z,
G. Sukhurukov y, A. Hobbs y, T. Chowdhury y. yQueen Mary, Univ. of
London, London, United Kingdom; zUniv. of Malaya, Kuala Lumpur,
Malaysia
Purpose: CNP exhibits potent anti-inﬂammatory and pro-anabolic
effects in chondrocytes. For example, the peptide blocked production of
nitric oxide (NO) and restored matrix synthesis in human chondrocytes
cultured with IL-1b. These anti-inﬂammatory effects indicate that CNP
has the potential to repair cartilage damage observed in osteoarthritis
(OA). However, there is a lack of effective treatments for OA due to poor
targeting of therapeutics into the articular joint, and agents that have a
short half-life. Recently, layer-by-layer preparation of microcapsules has
been developed as a depot system for the stable encapsulation and
sustained delivery of bioactive agents. The present study fabricated
multilayer polyelectrolyte microcapsules loaded with CNP, and exam-
ined whether this approach could have protective effects in cartilage
explants treated with IL-1b.
Methods: Microcapsules were prepared using layer-by-layer assembly
of a TRITC-labelled polyelectrolyte shell around a sacriﬁcial calcium
carbonate template loaded with 100mM FITC-conjugated CNP. Incor-
poration of labelled CNP was conﬁrmed by ﬂuorescence microscopy.
Encapsulation efﬁciency and CNP release were determined by ﬂuo-
rescence assay in supernatents taken during preparation and after
encapsulation, respectively. Microcapsule characteristics (morphology,
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punched from bovine articular cartilage were wounded with a scalpel
and equilibrated in culture for 24h. Explants were subsequently incu-
bated with 0 or 10ng/mL of IL-1b and/or microcapsules with or without
encapsulated CNP for 96h. At the end of the culture period, samples
were analysed for NO release and GAG loss (%). Chondrocyte % viability
was assessed by incubation with calcein-AM and EtBr-1(5mM), and
quantiﬁed by ImageJ analysis. Confocal microscopy was used to detect
interaction of CNP microcapsules by incubating chondrocytes with
antibodies to natriuretic peptide receptor (Npr) 2 and 3.
Results: SEM showed uniform, 2-3 mm spherical microcapsules with
morphological characteristics similar in templates loaded with or
without CNP. The protein was localized around the inner surface of the
microcapsule shell with encapsulation efﬁciencies >82.9%. CNP release
proﬁles were broadly similar following 1-9 days of culture. The pres-
ence of CNP microcapsules did not signiﬁcantly affect cell viability
(>80%), with DNA values that remained stable throughout theculture
conditions. Microcapsules were shown to localise to wounded areas of
the explants, and confocal imaging showed clustering of microcapsules
in chondrocytes to natriuretic peptide receptor (Npr) 2 and 3. Fur-
thermore, treatment of cartilage explants with CNP microcapsules led
to concentration-dependent inhibition of NO release in response to IL-
1band restoration of matrix synthesis.
Conclusions: The present study reproducibly generated uniform
microcapsules with homogeneous morphological characteristic suit-
able for delivery and retention in the articular joint. The microcapsule
delivery system is highly effective for CNP since the peptide could be
stabilised through electrostatic interaction with the polyelectrolyte
layers sufﬁcient to allow diffusion of active CNP after localisation to
areas of damage. Furthermore, treatment of cartilage explants with
bioactive concentrations of CNP led to protective effects with sustained
release of CNP in a manner responsive to the local environment. In
summary, we demonstrate for the ﬁrst time controlled delivery of CNP
to dampen inﬂammatory effects induced by IL-1bin cartilage explants
that has the potential to promote cartilage repair in vivo.
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OBESITY DOES NOT NEGATIVELY INFLUENCE CARTILAGE REPAIR OR
CAUSE OSTEOARTHRITIS IN DBA/1 MICE
W. Wei y, Y.M. Bastiaansen-Jenniskens y, K.P. Bos y, J.A. Verhaar y,
A.-M. Zuurmond y, F. Dell'Accio z, G.J. Van Osch y. y Erasmus Univ. Med.
Ctr., Rotterdam, Netherlands; zQueen Mary Univ., London, United
Kingdom
Purpose: Traumatic cartilage damage, if left untreated, could eventually
increase the risk of developing osteoarthritis (OA). Marrow stimulation
treatments, such as microfracture, are performed to stimulate intrinsic
cartilage repair. The symptomatic improvements of microfracture are
reported to be less in obese patients and these patients are now often
excluded from treatment. Obesity is a major risk factor for OA and leads
to low grade systemic inﬂammation and metabolic changes. There is
however no convincing evidence that intrinsic cartilage repair is neg-
atively inﬂuenced by obesity. To optimize cartilage repair treatments
and to prevent OA development in obese patients, it is therefore
essential to investigate whether and how obesity inﬂuences cartilage
repair. In this study we investigated the effects of obesity on cartilage
repair and OA development in the DBA/1 mouse strain. Our hypothesis
was that obesity negatively inﬂuences intrinsic cartilage repair and
accelerates the speed of OA development after cartilage damage.
Methods: Ten-weeks-old male DBA/1 mice were fed with control diet
or obesity inducing high fat diet (HFD; 60% energy from fat). After two
weeks, a full thickness cartilage defect wasmade in the trochlear groove
of the left knee. Mice were sacriﬁced after 1 (n¼6 mice per diet), 8 (n¼9
mice per diet) and 24 (n¼5 mice per diet) weeks. Cartilage repair was
evaluated on histology using the Pineda scoring method and OA
development was evaluated using the OARSI scoring method.
Results:Mice on a HFD had higher bodyweight whenmaking the defect
(31.0±1.7gr versus 27.2±1.1gr; p<0.001) and the difference became even
larger after 24 weeks (42.0±5.8gr versus 31.7±4.6gr; p<0.001). One
week after defect creation, mice on HFD had a higher percentage of
defect ﬁlling with ﬁbroblast-like cells in the defect. After 8 weeks, mice
on a HFD had more cartilage repair as indicated by a lower Pineda score(p¼0.01). After 24 weeks, no mice had complete cartilage repair and we
were not able to detect a statistically signiﬁcant difference in Pineda
score between mice on HFD and control diet with this group size. All
mice at every time point had an OARSI score of 0, indicating no signs of
osteoarthritis.
Conclusions: Obesity did not negatively affect intrinsic cartilage repair
in DBA/1 mice. Obesity did not cause OA in DBA/1 mice, even in com-
bination with induced traumatic cartilage damage. Future research into
the inﬂammatory and metabolic changes after a high fat diet in this
strain of mice could provide more insights into the link between obesity
related changes, cartilage damage and OA development.
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CARTILAGE TISSUE ENGINEERING USING ADAMTS-4/5 DEFICIENT
MESENCHYMAL STEM CELLS
D. Wang, S. Chen, M. Esterban, M. Tortorella. Guangzhou Inst.s of
biomedicine and Hlth., CAS, Guangzhou, China
Purpose: Aggrecan is one of the two major constituents of articular
cartilage, and during diseases such as osteoarthritis (OA) it is subject to
degradation by proteolytic enzymes. The primary proteases responsible
for aggrecan cleavage are the aggrecanases, identiﬁed as members of
the disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS) family of proteases. Aggrecanase 1(ADAMTS-4) and aggre-
canase 2 (ADAMTS-5) have been reported as important therapeutic
targets in osteoarthritis. However, there is still debate which of them is
the major aggrecanase responsible for the degradation of aggrecan in
human cartilage. The aim of this study was to generate ADAMTS-4
deﬁcient and ADAMTS-5 deﬁcient chondroprogenitors derived form
human induced pluripotent stem cells (iPSCs) to enable the evaluation
of the respective roles of ADAMTS-4 and ADAMTS-5 in human cartilage
breakdown.
Methods: ADAMTS-4 deﬁcient and ADAMTS-5 deﬁcient human iPS
cells were produced by knockout of these genes in iPS cells using
Transcription Activation-Like Effector nucleases (TALENs). These iPS
cells were differentiated into chondrogenic lineage via generation of
mesenchymal stem cells (MSCs) using a multistep culture method
consisting of embryoid body (EB) formation, cell outgrowth from EBs,
monolayer culture of sprouted cells from EBs, and 3-demensional pellet
culture. Interleukin-1 (IL-1) and tumor necrosis factor (TNF) treatment
were applied after chondrogenic differentiation. The expression of type
II collagen, aggrecan, ADAMTS4, and ADAMTS-5 was measured by
quantitative real-time PCR, Western blotting, and immunoﬂuorescence
staining. The production of collagen and glycosaminoglycan (GAG) was
quantiﬁed by dye binding assays.
Results: ADAMTS-4/5 deﬁcient iPSC-derived MSCs exhibited ﬁbroblast-
like morphology similar to bone marrow MSCs and expressed surface
markers for MSCs. After 4-6 weeks of pellet culture, cells in pellet
exhibited a spherical morphology typical of chondrocytes. The
expression of type II collagen and aggrecan in pellets progressively
increased. Histological analysis revealed that ADAMTS-4/5 deﬁcient
MSC-derived pellets successfully underwent chondrogenic
differentiation.
Conclusions: These results demonstrate a model system of chon-
droprogenitors from genetically modiﬁed human iPSCs. This work also
provides potential iPSC progeny for developing cell-base approaches to
repair joint cartilage damage.
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EXTRACELLULAR MATRIX CHANGES IN RESPONSE TO SPRIFERMIN
STUDIED IN EX VIVO CULTURES OF ARTICULAR CARTILAGE
D. Reker y, A. Gigout z, C. Ladel z, M. Karsdal y, A. Bay-Jensen y. yNordic
BioSci., Herlev, Denmark; zMerck KGaA, Darmstadt, Germany
Purpose: Osteoarthritis (OA) is a degenerative disease with high
prevalence, creating an unmet medical need for drugs to protect and
regenerate cartilage. Sprifermin, a truncated form of ﬁbroblast growth
factor 18 (rhFGF18), is being investigated as a potential disease-mod-
ifying OA drug (DMOAD). Sprifermin has been shown to increase car-
tilage volume in the knees of OA patients. The few studies published
about the mode of action behind its anabolic effects, indicate that full-
